Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $434.7 million.

  • Arrowhead Pharmaceuticals' Non-Current Assets fell 2.18% to $434.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.7 million, marking a year-over-year decrease of 2.18%. This contributed to the annual value of $434.7 million for FY2025, which is 2.18% down from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Non-Current Assets stood at $434.7 million, which was up 0.22% from $433.7 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Non-Current Assets registered a high of $444.3 million during Q3 2024, and its lowest value of $170.0 million during Q1 2021.
  • For the 3-year period, Arrowhead Pharmaceuticals' Non-Current Assets averaged around $401.9 million, with its median value being $433.7 million (2025).
  • Examining YoY changes over the last 5 years, Arrowhead Pharmaceuticals' Non-Current Assets showed a top increase of 71.05% in 2021 and a maximum decrease of 31.05% in 2021.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Non-Current Assets (Quarterly) stood at $300.3 million in 2021, then rose by 5.40% to $316.5 million in 2022, then grew by 22.72% to $388.4 million in 2023, then grew by 14.10% to $443.2 million in 2024, then decreased by 2.18% to $434.7 million in 2025.
  • Its last three reported values are $434.7 million in Q3 2025, $433.7 million for Q2 2025, and $438.3 million during Q1 2025.